

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **January 8, 2007**

Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-33137 (Commission File Number)	14-1902018 (IRS Employer Identification No.)
2273 Research Boulevard, Suite 400, Rockville, Maryland (Address of Principal Executive Offices)		20850 (Zip Code)

Registrant's telephone number, including area code: **(301) 795-1800**

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On January 8, 2007, Emergent BioSolutions Inc. announced expected total revenues for 2006 based on preliminary, unaudited results. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index attached hereto.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 8, 2007

EMERGENT BIOSOLUTIONS INC.

By: /s/ R. Don Elsey_____

R. Don Elsey

Vice President Finance, Chief

Financial Officer and Treasurer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated January 8, 2007

News Release

Media Contact:
Robert G. Burrows
Vice President, Corporate Communications
Emergent BioSolutions Inc.
301-795-1877
burrowsr@ebsi.com

EMERGENT BIOSOLUTIONS ANNOUNCES EXPECTED 2006 TOTAL REVENUE OF APPROXIMATELY \$150 MILLION

Expected 2006 Total Revenues Increase Approximately 15% From 2005

ROCKVILLE, MD, January 8, 2007—Emergent BioSolutions Inc. (NYSE: EBS) today announced that its total revenues for 2006 are estimated to be approximately \$150 million, based on the company's preliminary, unaudited results for full year 2006. This represents an increase of approximately 15% over 2005 total revenues of \$130.7 million. The company has not finalized its financial statements for 2006, and results are subject to change.

As previously announced, Fuad El-Hibri, president, chief executive officer and chairman of the board of directors of Emergent BioSolutions, will provide a company overview and outline future growth opportunities at the 25th Annual JPMorgan Healthcare Conference in San Francisco today at 3:00 pm PST at the St. Francis Hotel in San Francisco, California.

A webcast of the presentation will be available both live and by replay. To access both the live and archived webcast, please go to www.emergentbiosolutions.com, click on the "Investors" link and proceed to the "Webcasts & Presentations" section. The archived replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and therapeutics that induce or assist the body's immune system to prevent or treat disease. The company's biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that are potential weapons of bioterrorism. The company's commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical needs. More information on the company is available at www.emergentbiosolutions.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding expected 2006 total revenues and any other statements

containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including a revision to the company's preliminary, unaudited results for 2006 as a result of finalizing its audited financial statements and other factors identified in the company's Registration Statement on Form S-1 and subsequent reports filed with the Securities and Exchange Commission. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.